An Excessive Heat Warning is in effect on July 23, 2014 for La Paz, Maricopa, Pinal, and Yuma Counties until July 24, 2014 at 8:00 PM. Learn more about how to stay safe in extreme heat and stay informed about future heat alerts.

Arizona Cancer Registry

Cancer Case Reporting for Physicians and Clinics

Effective January 1, 1992, cancer became a reportable disease in Arizona. A.R.S. 36-133 requires clinics (freestanding outpatient clinics) and physicians to report cancer cases to the Arizona Cancer Registry (ACR). The reporting forms and the instructions are available below in PDF format.

If you have questions about how to complete the form or where to send it, please contact the Arizona Cancer Registry.

Definitions

  • Physician
    Includes all Doctors of Medicine, Doctors of Osteopathy, and Dentists.
  • Freestanding Outpatient Clinic
    Means every health care institution, whether organized for profit or not, which is not a hospital and which provides outpatient cancer diagnosis and treatment of 100 or more cancer cases per year, including outpatient surgical facilities, staff-based health maintenance organizations, multispecialty clinics, and outpatient radiation therapy facilities. (Clinics seeing less than 100 cancer cases per year are to follow the reporting requirements for physicians.)

Reporting Requirements

  • Physicians
    Must report cancer cases in the following two instances:
    1. If the ACR receives a pathology report of a cancer case not already reported by a hospital or cancer clinic, the ACR will send the physician a partially completed report form. The physician is required to verify and correct (if necessary) the accuracy of the report form, complete any blanks, and send the form back to the ACR within 30 days.
    2. Physicians are required to initiate a report within 30 days of diagnosis for cancer cases meeting all the following criteria:
      • Not seen in an Arizona hospital;
      • Not seen in a cancer clinic (one that sees >100 cases per year);
      • Not confirmed by a pathology lab licensed in Arizona.
  • Freestanding Outpatient Clinics
    Outpatient clinics are required to submit a case report for cancer cases not referred to a hospital. The clinic must designate a doctor or cancer registrar to submit case reports as described below within 90 days of diagnosis or initiation of treatment at the clinic. Clinics reporting more than 100 cases yearly must code and submit the information electronically.

Which Cancers Are Reportable?

  • What Is Reportable
    A reportable case is defined as: any malignant neoplasm (solid or hematopoietic); carcinoma in situ; or benign tumor of the central nervous system and pineal and pituitary glands. (Please see information below regarding hematopoietic diseases reportable as of January 1, 2001.)
  • What Is Not Reportable
    1. All non-genital, primary skin (ICD-O Sites C44.0 - C44.9) cancers of the following types and histologies (diagnosed on or after January 1, 2003):
      • Neoplasms, malignant, NOS of skin (8000-8004)
      • Epithelial carcinomas of the skin (8000-8045)
      • Papillary and squamous cell carcinomas of the skin (8050-8082)
      • Basal cell carcinomas of any site (8090-8110).

      Note: Prior to January 1, 2003, the above skin cancers were reportable if staged regional or distant at the time of diagnosis.

      Basal or squamous cell cancers of the skin of the lip, eyelid, or nose ARE NOT reportable, but any cancers of the mucosa of these sites ARE reportable.

    2. Carcinoma in-situ of the cervix (diagnosed on or after January 1, 1994).

Hematopoietic Diseases: Codes or Diagnosis Reportable as of January 1, 2001

  • Plasma cell tumors
    • 9733/3 Plasma cell leukemia
  • Mast cell tumors
    • 9742/3 Mast cell leukemia
  • Neoplasms of histiocytes (macrophages) and accessory lymphoid(antigen presenting) cells
    • 9751/1 – The Langerhans cell histiocytosis
    • 9754/3
    • 9755/3 Histiocytic sarcoma
    • 9756/3 Langerhans cell sarcoma
    • 9757/3 Interdigitating dendritic cell sarcoma
    • 9758/3 Follicular dendritic cell sarcoma
  • Selected myeloid leukemias
    • 9920/3 Therapy-related acute myeloid leukemia, NOS
  • Other leukemias
    • 9945/3 Chronic myelomonocytic leukemia
    • 9946/3 Juvenile myelomonocytic leukemia
    • 9948/3 Aggressive NK-cell leukemia
  • Chronic myeloproliferative disorders
    • 9950/3 Polycythemia vera
    • 9960/3 Chronic myeloproliferative disease
    • 9961/3 Myelosclerosis with myeloid metaplasia
    • 9962/3 Essential thrombocythemia
    • 9963/3 Chronic neutrophilic leukemia
    • 9964/3 Hypereosinophilic syndrome
  • Myelodysplastic syndromes
    • 9980/3 Refractory anemia
    • 9982/3 Refractory anemia with sideroblasts
    • 9983/3 Refractory anemia with excess blasts
    • 9984/3 Refractory anemia with excess blasts in transformation
    • 9985/3 Refractory cytopenia with multilineage dysplasia
    • 9986/3 Myelodysplastic syndrome with 5-q syndrome
    • 9987/3 Therapy-related Myelodysplastic syndrome, NOS
    • 9989/3 Myelodysplastic syndrome, NOS

Note: Information provided in PDF files, unless otherwise indicated.